Eiger BioPharmaceuticals, Inc. Uncategorized Contracts & Agreements
29 Contracts & Agreements
- Promotion Letter Agreement, dated as of September 21, 2023, by and between Eiger BioPharmaceuticals, Inc. and Ingrid Choong (Filed With SEC on November 9, 2023)
- Offer Letter Agreement, dated as of (Filed With SEC on August 14, 2023)
- Offer Letter Agreement, dated as of January 9, 2023, by and between Eiger BioPharmaceuticals, Inc. and David Apelian (Filed With SEC on March 17, 2023)
- Open Market Sale AgreementSM, dated March 25, 2022, by and between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 25, 2022)
- Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Erik Atkisson, dated as of August 26, 2021 (Filed With SEC on November 4, 2021)
- 2021 Inducement Plan (Filed With SEC on August 5, 2021)
- Open Market Sale AgreementSM, dated August 6, 2020, between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 6, 2020)
- Offer Letter Agreement, by and between the Registrant and Eldon Mayer, dated as of December 3, 2019 (Filed With SEC on May 7, 2020)
- Description of Registrants Securities (Filed With SEC on March 13, 2020)
- Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and James Shaffer (Filed With SEC on November 7, 2019)
- Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Stephana E. Patton (Filed With SEC on November 7, 2019)
- Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on November 7, 2019)
- Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and David A. Cory (Filed With SEC on November 7, 2019)
- Offer Letter, dated as of November 30, 2018, by and between Eiger BioPharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on May 9, 2019)
- Offer Letter, dated as of February 26, 2019, by and between Eiger BioPharmaceuticals, Inc. and Stephana Patton (Filed With SEC on May 9, 2019)
- Offer Letter, dated as of December 12, 2017, by and between Eiger BioPharmaceuticals, Inc. and David Apelian, M.D., Ph.D (Filed With SEC on March 9, 2018)
- EXCLUSIVE AGREEMENT (Filed With SEC on December 14, 2015)
- EXCLUSIVE AGREEMENT (Filed With SEC on December 14, 2015)
- L E A S E (Filed With SEC on December 14, 2015)
- SUPPORT AGREEMENT (Filed With SEC on November 19, 2015)
- SUPPORT AGREEMENT (Filed With SEC on November 19, 2015)
- Material Transfer and Exclusivity Agreement (Filed With SEC on May 13, 2014)
- INDEMNITY AGREEMENT (Filed With SEC on November 8, 2013)
- Additional abbreviations may also be used though not in the above list. For value received, hereby sell(s), assign(s) and transfer(s) unto (Filed With SEC on October 29, 2013)
- SUBLICENSEAGREEMENT (Filed With SEC on October 11, 2013)
- FOR THE PARTYOF THE FIRST PART Frank L. Graham President & Chief Executive Officer AdVec Inc. Ancaster, Ontario CANADA FOR THE PARTY OF THESECOND PART CELLADON CORPORATION 2223... (Filed With SEC on October 11, 2013)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on October 11, 2013)
- LICENSEAGREEMENT BETWEEN CELLADONCORPORATION AND THE REGENTSOF THE UNIVERSITY OF CALIFORNIA FOR CASE NO. [...***...] CASE NO. [...***...] CASE NO.[...***...] CASE NO. [...***...]... (Filed With SEC on October 11, 2013)
- INDEMNITY AGREEMENT (Filed With SEC on October 11, 2013)
